NYSE:TEVAPharmaceuticals
Duvakitug IBD Data and TEV-749 Filing Might Change The Case For Investing In Teva (TEVA)
In February 2026, Sanofi and Teva Pharmaceutical Industries reported that duvakitug, an investigational TL1A-targeting antibody, achieved durable 44-week clinical and endoscopic efficacy with consistent safety in ulcerative colitis and Crohn’s disease responders in the RELIEVE UCCD long-term extension study.
A separate recent milestone saw the US FDA accept Teva’s New Drug Application for TEV-749, a once-monthly olanzapine injection for adult schizophrenia, underscoring the company’s push...